Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-CCR2 SPECT probe
- Development stage
- Preclinical
- Lead developer
- Beijing Institute of Respiratory Medicine
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
99mTc-CCR2 SPECT probe is a radiolabeled single-photon emission computed tomography (SPECT) imaging agent designed to target C-C chemokine receptor type 2 (CCR2). Developed by researchers at the Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, the probe is radiolabeled with technetium-99m (99mTc) to enable non-invasive visualization of CCR2-expressing cells, such as immunosuppressive monocytes and tumor-associated macrophages (TAMs), within the tumor microenvironment. In preclinical models of non-small cell lung cancer (NSCLC), including lung metastasis and patient-derived xenografts, the probe demonstrated high specificity and excellent tumor uptake, correlating with CCR2+ stromal immune infiltrates. It is being investigated as a translational biomarker for patient stratification and prognosis in NSCLC.
- Other names
- 99mTc-CCR2CCR2-targeted SPECT probeCCR-2-targeted SPECT probeCCR 2-targeted SPECT probe
02
Targets
CCR2 (Chemokine (C-C motif) Receptor 2)
Beyond the preview
Go deeper on 99mTc-CCR2 SPECT probe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-CCR2 SPECT probe.